Zilebesiran
zilebesiran
PHASE3
Drug Profile
ModalitysiRNA
RouteSC
Therapy AreaCVRM
Peak Sales Est$4200M
Formulations[{"id":"zile-sc","route":"SC","setting":"HCP_ONLY","frequency":"Every 3-6 months","is_primary":true}
Mechanism: Angiotensinogen silencing
Expert: Hepatocyte-targeted siRNA silencing AGT gene expression, reducing angiotensinogen production for durable blood pressure control.
Everyday: A gene-silencing injection that stops the liver from making a protein that raises blood pressure, providing months-long control.
Targets: ["AGT"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| Hypertension | PHASE3 | ZENITH | [] |
Clinical Studies (1)
Primary EP: [{"id":"zen-pe1","name":"Systolic Blood Pressure Reduction","type":"PRIMARY","unit":"mmHg","results":[]}]
Efficacy: Large CV outcomes-oriented program. Testing 3-6 month dosing. Addressing adherence challenge in hypertension.
Upcoming Catalysts (1)
Zilebesiran - Hypertension - Ph3 - Topline
2027
Notes
AGT-targeting siRNA for hypertension. 3-6 month dosing. ZENITH Ph3 ongoing. Could transform BP control adherence. Parry: $4.2bn peak.
Data from Supabase · Updated 2026-03-24